RPRX — Royalty Pharma plc stock price, charts and financials

QT78Royalty Pharma plc

Royalty Pharma plc (NASDAQ: RPRX) is a Healthcare company in the Medical - Pharmaceuticals industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
57.17
-1.26-2.16%
OverviewShort InterestFilings
RPRXQT78Royalty Pharma plc·NASDAQ
57.17-2.16%
Earnings
Down 2.2% — Earnings due 2026-08-05 — pre-report positioning.
Medium confidence
TA
Loading chart...
Screen all →
CORT-1.48%$112.80LQDA-0.31%$83.85KNSA-1.25%$73.41TRLV-0.58%$8.60LH-0.58%$307.42PHG-0.27%$26.23WAT-0.68%$374.74DGX-0.45%$231.95
Snapshot
Index-P/E23.71EPS (ttm)2.46Insider Own24.22%Shs Outstand430.12MPerf Week-0.68%
Market Cap25.13BForward P/E10.44EPS next Y5.60Insider Trans-0.65%Shs Float413.50MPerf Month4.75%
Enterprise Value33.50BPEG-EPS next Q-Inst Own-Short Float2.93%Perf Quarter16.65%
Income824.33MP/S10.30EPS this Y195.27%Inst Trans-Short Ratio3.28Perf Half Y43.00%
Sales2.44BP/B3.66EPS next Y7.10%ROA4.18%Short Interest12.13MPerf YTD51.22%
Book/sh-P/C9.51EPS next 5Y9.67%ROE12.67%52W High59.14 -3.33%Perf Year57.41%
Cash/sh-P/FCF9.47EPS past 3/5Y162.07% 7.06%ROIC8.43%52W Low33.34 71.45%Perf 3Y87.16%
Dividend Est.0.94 (1.64%)EV/EBITDA19.72Sales past 3/5Y2.06% 2.30%Gross Margin99.95%Volatility1.87% 2.21%Perf 5Y44.88%
Dividend TTM0.91 (1.59%)EV/Sales13.73EPS Y/Y TTM-7.33%Oper. Margin67.93%ATR (14)1.28Perf 10Y-
Dividend Ex-DateAug 14, 2026Quick Ratio2.66Sales Y/Y TTM7.82%Profit Margin33.91%RSI (14)55.15Recom2.00
Dividend Gr. 3/5Y5.01% 24.01%Current Ratio2.66EPS Q/Q22.64%SMA200.72%Beta0.43Target Price56.67
Payout46.81%Debt/Eq1.30Sales Q/Q11.09%SMA504.13%Rel Volume0.59Prev Close58.43
Employees100LT Debt/Eq0.88EarningsAug 05SMA20025.81%Avg Volume3.63MPrice57.17
IPO DateJun 16, 2020Option/ShortYes / YesEPS/Sales Surpr.7.11% 4.91%Net Debt/EBITDA4.93Volume2,149,546Change-2.16%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-21-26ReiteratedUBSBuy$49 → $57
Apr-10-26ReiteratedMorgan StanleyOverweight$61 → $63
Feb-27-26ReiteratedSeaport Global$50
Feb-12-26ReiteratedMorgan StanleyOverweight$56 → $61
Jan-30-26UpgradeUBSNeutral → Buy$28 → $49
Dec-11-25ReiteratedLeerink Partners$45
Sep-30-25InitiatedGoldman SachsBuy$51 → $42
Jul-10-25ReiteratedMorgan StanleyOverweight$51 → $54
Sep-04-24ReiteratedGoldman SachsBuy$50 → $51
Jun-07-24ReiteratedGoldman SachsBuy$50
Latest News
Today
Today08:15AM
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiativesglobenewswire.com
Jul-29-26
Jul-29-2611:02AM
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Releasezacks.com
Jul-23-26
Jul-23-2604:07AM
Bank of New York Mellon Corp Reduces Stock Position in Royalty Pharma PLC $RPRXdefenseworld.net
Jul-22-26
Jul-22-2607:05AM
Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmuneglobenewswire.com
06:54AM
Neurimmune Sells Portion Of Its Royalty Interest In Cliramitug To Royalty Pharma For Up To $425M, Including $125M UpfrontBenzinga
Jul-21-26
Jul-21-2603:13AM
Royalty Pharma PLC $RPRX Holdings Lowered by AlTi Global Inc.defenseworld.net
Jul-20-26
Jul-20-2608:30AM
ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)SeekingAlpha
Jul-19-26
Jul-19-2604:11AM
Chicago Partners Investment Group LLC Purchases New Position in Royalty Pharma PLC $RPRXdefenseworld.net
Jul-17-26
Jul-17-2604:15PM
Royalty Pharma declares third quarter 2026 dividendglobenewswire.com
10:01AM
Why Investors Need to Take Advantage of These 2 Medical Stocks Nowzacks.com
Jul-15-26
Jul-15-2604:15PM
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026globenewswire.com
Jul-14-26
Jul-14-2604:48PM
A Fresh Look At Syndax PharmaceuticalsSeekingAlpha
Jul-13-26
Jul-13-2609:56AM
Why Investors Need to Take Advantage of These 2 Medical Stocks Nowzacks.com
Jul-10-26
Jul-10-2601:10PM
Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Againzacks.com
01:01PM
Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choicezacks.com
Company

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,4412,3782,2642,3552,2372,2892,1221,8141,795
Cost of Goods Sold Incl. D&A
100000000
Gross Profit2,4392,3782,2642,3552,2372,2892,1221,8141,795
Selling, General and Administrative Excl. Other62257323725022718318210362
Research and Development4434522521772002683393
Other Operating Expense-283-2067325601,526476319-995-25
Operating Income1,6571,5601,2921,4923071,4311,5952,6231,364
Interest Expense337308226187188166157269280
Unusual Expense
—————————
Non-Operating Income (Expense)3872264395111-23264107433
Net Income Before Taxes1,3591,3241,3311,7002301,2411,7022,4611,518
Income Taxes
000000000
Consolidated Net Income8277718591,135436209752,3491,378
Net Income From Continuing Operations1,3591,3241,3311,7002301,2411,7022,4611,518
Net Income8277718591,135436209752,3491,378
EPS (Recurring)2.462.331.923.410.101.491.286.633.89
EPS (Basic, Before Extraordinaries)2.462.331.923.410.101.491.286.633.89
EPS (Diluted)1.771.801.912.530.101.491.286.633.89
EBITDA1,6981,6361,5561,8874241,4301,8822,7541,831
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio32.3021.4713.3611.10395.2026.7439.10——
Price To Sales Ratio10.127.025.035.347.747.229.15——
Gross Margin99.92100.00100.00100.00100.00100.00100.00100.00100.00
Operating Margin67.8865.6057.0763.3513.7262.5275.16144.6075.99
Net Margin33.8832.4237.9448.201.9227.0945.95129.4976.77
Shares Outstanding432432446448438415388354354
Market Capitalization24,69716,69211,37712,58417,31016,53819,419——
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$64.12$55.13$46.14$37.15$28.16● Close Price0.00M4.92M9.83M14.75M19.67MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Urist MarshallEVP, Research & InvestmentsJul 01 '26Sale55.889,099508,4540Jul 02
Urist MarshallEVP, Research & InvestmentsJun 24 '26Sale55.189,098502,0679,099Jun 25
Hite ChristopherEVP & Chairman, PartneringJun 23 '26Sale54.40150,0008,159,277559,399Jun 25
Coyne Terrance P.EVP & CFOMay 26 '26Sale53.9864,3993,476,1160May 28
Urist MarshallEVP, Research & InvestmentsMay 20 '26Sale52.7513,684721,83818,197May 21
Urist MarshallEVP, Research & InvestmentsMay 14 '26Sale53.0613,684726,13731,881May 15
Norden GregoryDirectorMay 14 '26Sale53.003,045161,385191,803May 15
Coyne Terrance P.EVP & CFOApr 28 '26Sale49.7834,7911,731,8410Apr 30
Coyne Terrance P.EVP & CFOApr 01 '26Sale48.3334,7911,681,51232,916Apr 02
Coyne Terrance P.EVP & CFOMar 23 '26Sale45.5334,7911,583,98943,886Mar 25
Coyne Terrance P.EVP & CFOMar 02 '26Sale46.7834,7911,627,53445,761Mar 04
Coyne Terrance P.EVP & CFOFeb 23 '26Sale45.3234,7911,576,60647,636Feb 25
Coyne Terrance P.EVP & CFOFeb 04 '26Sale43.2920,163872,91222,885Feb 04
Coyne Terrance P.EVP & CFOFeb 03 '26Sale42.84114,9544,924,99723,972Feb 04
Coyne Terrance P.EVP & CFOFeb 02 '26Sale42.08108,4244,562,90530,167Feb 04
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.